Prosight Ltd. XRF-GUIDED biopsy - a Novel Modality in Prostate Cancer

ProSight developed a novel modality in prostate cancer. Our invention – based on knowhow from the Weizmann Institute of Science – allows workflow-neutral use of the hallmark biomarker of prostate cancer in the clinical flow, potentially doubling detection-rate and cancer-grading accuracy. Successful clinical study with a prototype; one granted patent, one pending; article published; plans for FDA 510(k) in 18 months and launching in two years.